Report (By reporter Meng Tingting) On the evening of December 7, Haichuang Pharmaceutical Co., Ltd. (hereinafter referred to as "Haichuang Pharmaceutical") announced that its independently developed Deuterium Enzalutamide Soft Capsules passed national medical insurance negotiations and were included in the National Medical Insurance Drug Catalog for the first time. The catalog will be implemented starting January 1, 2026.
Deuterium Enzalutamide Soft Capsules (previously known as: HC-1119 Soft Capsules) are a Class 1 new drug independently developed by Haichuang Pharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a second-generation androgen receptor (AR) inhibitor and received support from the National Science and Technology Major Project for "Major New Drug Innovation and Development".
These capsules are the first domestically produced innovative drug approved in China for mCRPC patients who have progressed after abiraterone acetate and chemotherapy and have not received a novel AR inhibitor. Compared to other endocrine drugs, Deuterium Enzalutamide Soft Capsules demonstrate superior safety, reducing central nervous system adverse events and rash-related reactions, and lowering the risk of complications in elderly patients. The 2025 CSCO Guidelines for Prostate Cancer recommend this treatment for mCRPC.
Inclusion in the 2025 National Medical Insurance Drug Catalog is seen as recognition of the drug's clinical value and potential patient benefits. This move is anticipated to aid market access, lower costs for patients, and improve drug availability. Haichuang Pharmaceutical reportedly intends to work towards policy implementation and expand market coverage.

https://finance.eastmoney.com/a/202512073584617642.html